Radnostix reported decreased revenue in the second quarter of the 2026 fiscal year, which ended June 30.
The company reported a total revenue of $2.67 million in the quarter, down 27% from $3.66 million in the same period in 2025. It said declines were driven by residual effects of two voluntary product recalls and the Cobalt-60 hot-cell shutdown.
Net loss for the quarter was $0.88 million, compared with $0.16 million in the prior-year period. For the six months ended June 30, 2026, total revenue was $5.05 million, down 27% from $6.89 million in the first half of 2025. And net loss was $2.23 million versus $0.27 million in the prior-year period, the company said.
Radnostix said capsule inventory was fully restored by the end of June 2026 and customer volumes normalized in July. It added that both voluntary recalls have been fully executed, with all required documentation submitted to the U.S. Food and Drug Administration (FDA) in June.
